Table 1 Clinical attributes of TNBC patients from CPTAC, TCGA, METABRIC and MET500 by TNBC subtype.
| Â | Â | Â | TNBC | Basal-like 1 | Basal-like 2 | Mesenchy-mal | Luminal AR |
|---|---|---|---|---|---|---|---|
Primary | Datasets | CPTAC | 27 | 11 (40.7%) | 3 (11.1%) | 9 (33.3%) | 4 (14.8%) |
TCGA | 183 | 64 (35.0%) | 37 (20.1%) | 54 (29.5%) | 28 (15.3%) | ||
METABRIC | 348 | 124 (35.6%) | 70 (20.1%) | 71 (20.4%) | 83 (23.9%) | ||
Age | Â | 55.7 | 52.7 | 57.9 | 54.8 | 59.9 | |
Stage | I | 120 (26.0%) | 36 (22.6%) | 22 (24.1%) | 30 (27.0%) | 32 (33.3%) | |
II | 252 (52.7%) | 101 (63.5%) | 46 (50.5%) | 59 (53.2%) | 46 (47.9%) | ||
III | 75 (16.2%) | 20 (12.6%) | 23 (25.3%) | 20 (18.0%) | 12 (12.5%) | ||
IV | 3 (0.7%) | 1 (0.6%) | 0 (0.0%) | 2 (1.8%) | 0 (0.0%) | ||
Histology | IDC | 476 (85.8%) | 174 (87.9%) | 89 (81.7%) | 116 (87.2%) | 97 (82.9%) | |
ILC | 26 (4.9%) | 4 (2.1%) | 3 (2.8%) | 4 (3.2%) | 15 (13.5%) p = 8.88e−6 | ||
Mixed | 1 (0.1%) | 1 (1.6%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
Mucinous | 1 (0.1%) | 1 (1.6%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
Medullary | 29 (5.6%) | 18 (9.6%) p = 0.0041 | 7 (6.5%) | 1 (1.8%) | 3 (2.7%) | ||
Metaplastic | 14 (2.6%) | 0 (0.0%) | 7 (13.5%) p = 0.011 | 6 (5.6%) | 1 (0.8%) | ||
Phyllodes tumor | 4 (0.8%) | 0 (0.0%) | 0 (0.0%) | 4 (3.2%) p = 0.0026 | 0 (0.0%) | ||
Neuroendocrine | 1 (0.1%) | 0 (0.0%) | 0 (0.0%) | 1 (1.8%) | 0 (0.0%) | ||
Secretory | 1 (0.1%) | 0 (0.0%) | 1 (0.9%) | 0 (0.0%) | 0 (0.0%) | ||
Papillary | 1 (0.1%) | 0 (0.0%) | 1 (0.9%) | 0 (0.0%) | 0 (0.0%) | ||
Other | 2 (0.3%) | 0 (0.0%) | 1 (0.9%) | 1 (0.8%) | 0 (0.0%) | ||
NA | 4 (0.8%) | 1 (1.6%) | 1 (0.9%) | 0 (0.0%) | 2 (1.7%) | ||
Metastatic | Datasets | MET500 | 40 | 11 (27.5%) | 10 (25.0%) | 8 (20.0%) | 10 (25.0%) |
